Cyprotex strikes research deal with Pfizer

DRUG testing specialist Cyprotex has struck a new deal with pharmaceutical giant Pfizer.

The Macclesfield firm’s US-based Apredica subsdiary, which it acquired in 2010, will take part in an 18-month collaborative research project with Pfizer.

The firm said the collaboration was a research-based project which aims to, “evaluate, further develop, and improve several of Cyprotex’s proprietary offerings in the area of predictive toxicology”.
 
Chief executive Dr Anthony Baxter said: “We are delighted to be able to continue our relationship with Pfizer. This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction.

“Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients.”

Cyprotex develops software that large pharmaceutical firms use to predict what the effect of their medication will be on a patient.